Cue Biopharma Files 8-K: Material Agreement, Financials

Ticker: CUE · Form: 8-K · Filed: Nov 6, 2025 · CIK: 1645460

Sentiment: neutral

Topics: material-agreement, financials, corporate-actions

Related Tickers: CUE

TL;DR

Cue Biopharma (NASDAQ: CUE) filed an 8-K today, reporting a material definitive agreement and financial statements.

AI Summary

On November 6, 2025, Cue Biopharma, Inc. filed an 8-K report. The filing indicates a material definitive agreement was entered into, and also includes Regulation FD disclosures and financial statements. The company, formerly known as Imagen Biopharma, Inc., is incorporated in Delaware and headquartered in Boston, Massachusetts.

Why It Matters

This 8-K filing signals a significant development for Cue Biopharma, Inc., potentially involving a new material agreement that could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the filing of financial statements suggests ongoing operational and financial activities that warrant attention.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Cue Biopharma, Inc.?

The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.

What specific financial statements are included in this 8-K filing?

The filing states that 'Financial Statements and Exhibits' are included, but the specific financial statements (e.g., balance sheet, income statement) are not detailed in the provided text.

When was Cue Biopharma, Inc. formerly known as Imagen Biopharma, Inc.?

The date of the name change from Imagen Biopharma, Inc. to Cue Biopharma, Inc. was June 17, 2015.

What is the primary business of Cue Biopharma, Inc. according to its SIC code?

Cue Biopharma, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Where are Cue Biopharma, Inc.'s principal executive offices located?

The principal executive offices of Cue Biopharma, Inc. are located at 40 Guest Street, Boston, Massachusetts 02135.

Filing Stats: 1,316 words · 5 min read · ~4 pages · Grade level 14.9 · Accepted 2025-11-06 08:03:53

Key Financial Figures

Filing Documents

01

Item 1.01. Entry into a Material Definitive Agreement. On November 6, 2025, ImmunoScape Pte. Ltd. ("IMSCP") exercised its option (the "Option") to obtain licenses to research, develop and commercialize molecules from Cue Biopharma, Inc.'s (the "Company") CUE-100 Series, including CUE-101 and CUE-102, subject to certain exclusions (the licensed series of molecules, the "Licensed Program"), for all oncology indications pursuant to a Collaboration and License Agreement, effective November 6, 2025, between the Company and IMSCP (the "Collaboration and License Agreement"). The licenses include a co-exclusive development license for five years or, if longer, for so long as IMSCP has a specified number of CUE-100 Series molecules under active development and, pursuant to which, the Company retains non-exclusive research rights to support its other programs (the "co-exclusive development license"). The licenses also include an exclusive commercial license to IMSCP for any CUE-100 Series molecule that IMSCP advances to IND-enabling studies while the co-exclusive development license is in effect. The Licensed Program will be further developed and potentially commercialized by IMSCP. The Option was exercised pursuant to an Option Agreement between the Company and IMSCP, dated October 22, 2025 (the "Option Agreement"). In connection with entry into the Option Agreement and IMSCP's exercise of the Option, the Company received an aggregate of $5 million in the fourth quarter of 2025. Pursuant to the Collaboration and License Agreement, the Company is entitled to receive (a) equity of IMSCP equal to 40% of the issued and outstanding equity of IMSCP and additional equity, in the form of warrants, upon certain dilution events in the future, (b) a time-based payment of $5 million in or prior to December 2025, (c) an additional time-based payment of $5 million before the first anniversary of the Option exercise, (d) high single-digit royalties on global net sales and (e) low- to m

01

Item 7.01. Regulation FD Disclosure On November 6, 2025, the Company issued a press release announcing the Collaboration and License Agreement. A copy of the press release is furnished hereto as Exhibit 99.1. The information in Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated November 6, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the Company's potential receipt of certain time-based milestone payments as well as royalty payments on net sales. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "anticipate," "believe," "continue," "could," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "predict," "project," "seek," "strategy," "future," "vision," "should," "target," "will," "would," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the company's ability to maintain its collaboration with IMSCP; the Company's limited operating history, limited cash and a history of losses; the Company's ability to achieve profitability; the Company's ability to obtain adequate financing to fund its business operations in the future; the Company's ability to successfully remediate its current "going concern" determination that it does not have sufficient capital on hand to continue operations beyond the next twelve months

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cue Biopharma, Inc. Date: November 6, 2025 By: /s/ Usman Azam Name: Usman Azam Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing